vs

Side-by-side financial comparison of Absci Corp (ABSI) and OneMedNet Corp (ONMD). Click either name above to swap in a different company.

OneMedNet Corp is the larger business by last-quarter revenue ($890.0K vs $650.0K, roughly 1.4× Absci Corp). OneMedNet Corp runs the higher net margin — -352.8% vs -4548.0%, a 4195.2% gap on every dollar of revenue. On growth, OneMedNet Corp posted the faster year-over-year revenue change (3323.1% vs -2.3%). OneMedNet Corp produced more free cash flow last quarter ($-1.7M vs $-29.3M). Over the past eight quarters, OneMedNet Corp's revenue compounded faster (89.4% CAGR vs -14.9%).

Absci Corp is a synthetic biology and AI-powered biotech firm focused on advancing next-generation biologic drug discovery and development. It delivers integrated protein engineering solutions to pharmaceutical and biopharmaceutical partners, enabling faster creation of novel antibodies, therapeutic proteins and other complex biologic candidates to address unmet global medical needs.

OneMedNet Corp is a U.S.-headquartered healthcare tech firm offering secure cloud-based data sharing and workflow solutions for medical imaging and patient health information. It serves healthcare providers, insurance payers, and life sciences groups, with its core operating market centered in North America.

ABSI vs ONMD — Head-to-Head

Bigger by revenue
ONMD
ONMD
1.4× larger
ONMD
$890.0K
$650.0K
ABSI
Growing faster (revenue YoY)
ONMD
ONMD
+3325.3% gap
ONMD
3323.1%
-2.3%
ABSI
Higher net margin
ONMD
ONMD
4195.2% more per $
ONMD
-352.8%
-4548.0%
ABSI
More free cash flow
ONMD
ONMD
$27.6M more FCF
ONMD
$-1.7M
$-29.3M
ABSI
Faster 2-yr revenue CAGR
ONMD
ONMD
Annualised
ONMD
89.4%
-14.9%
ABSI

Income Statement — Q4 2025 vs Q4 2025

Metric
ABSI
ABSI
ONMD
ONMD
Revenue
$650.0K
$890.0K
Net Profit
$-29.6M
$-3.1M
Gross Margin
20.7%
Operating Margin
-4775.5%
-353.4%
Net Margin
-4548.0%
-352.8%
Revenue YoY
-2.3%
3323.1%
Net Profit YoY
-2.0%
-32.3%
EPS (diluted)
$-0.19
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABSI
ABSI
ONMD
ONMD
Q4 25
$650.0K
$890.0K
Q3 25
$378.0K
$177.0K
Q2 25
$593.0K
$155.0K
Q1 25
$1.2M
$137.0K
Q4 24
$665.0K
$26.0K
Q3 24
$1.7M
$142.0K
Q2 24
$1.3M
$227.0K
Q1 24
$898.0K
$248.0K
Net Profit
ABSI
ABSI
ONMD
ONMD
Q4 25
$-29.6M
$-3.1M
Q3 25
$-28.7M
$-741.0K
Q2 25
$-30.6M
$3.0M
Q1 25
$-26.3M
$-1.9M
Q4 24
$-29.0M
$-2.4M
Q3 24
$-27.4M
$-2.1M
Q2 24
$-24.8M
$-3.6M
Q1 24
$-22.0M
$-2.1M
Gross Margin
ABSI
ABSI
ONMD
ONMD
Q4 25
20.7%
Q3 25
-125.4%
Q2 25
-155.5%
Q1 25
-163.5%
Q4 24
-100.0%
Q3 24
-59.2%
Q2 24
-44.9%
Q1 24
-27.8%
Operating Margin
ABSI
ABSI
ONMD
ONMD
Q4 25
-4775.5%
-353.4%
Q3 25
-7977.2%
-1262.7%
Q2 25
-5293.9%
-1331.0%
Q1 25
-2351.9%
-1623.4%
Q4 24
-4477.3%
-10438.5%
Q3 24
-1698.7%
-1645.1%
Q2 24
-2104.0%
-1081.1%
Q1 24
-2616.7%
-847.2%
Net Margin
ABSI
ABSI
ONMD
ONMD
Q4 25
-4548.0%
-352.8%
Q3 25
-7594.2%
-418.6%
Q2 25
-5155.0%
1923.9%
Q1 25
-2234.6%
-1388.3%
Q4 24
-4358.3%
-9126.9%
Q3 24
-1610.7%
-1449.3%
Q2 24
-1948.8%
-1581.1%
Q1 24
-2447.1%
-850.4%
EPS (diluted)
ABSI
ABSI
ONMD
ONMD
Q4 25
$-0.19
$-0.06
Q3 25
$-0.20
$-0.01
Q2 25
$-0.24
$0.07
Q1 25
$-0.21
$-0.06
Q4 24
$-0.26
$-0.07
Q3 24
$-0.24
$-0.07
Q2 24
$-0.22
$-0.14
Q1 24
$-0.22
$-0.08

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABSI
ABSI
ONMD
ONMD
Cash + ST InvestmentsLiquidity on hand
$144.3M
$585.0K
Total DebtLower is stronger
$220.0K
Stockholders' EquityBook value
$189.4M
$-3.0M
Total Assets
$216.3M
$2.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABSI
ABSI
ONMD
ONMD
Q4 25
$144.3M
$585.0K
Q3 25
$152.5M
$149.0K
Q2 25
$38.0M
$122.0K
Q1 25
$47.0M
$144.0K
Q4 24
$112.4M
$172.0K
Q3 24
$38.2M
$1.9M
Q2 24
$42.9M
$407.0K
Q1 24
$58.8M
$174.0K
Total Debt
ABSI
ABSI
ONMD
ONMD
Q4 25
$220.0K
Q3 25
Q2 25
Q1 25
$2.3M
Q4 24
$4.0M
$2.3M
Q3 24
$2.3M
Q2 24
$2.4M
Q1 24
Stockholders' Equity
ABSI
ABSI
ONMD
ONMD
Q4 25
$189.4M
$-3.0M
Q3 25
$210.3M
$-3.9M
Q2 25
$173.4M
$-3.8M
Q1 25
$198.8M
$-16.6M
Q4 24
$179.1M
$-15.9M
Q3 24
$201.3M
$-14.3M
Q2 24
$221.5M
$-19.2M
Q1 24
$240.1M
$-15.7M
Total Assets
ABSI
ABSI
ONMD
ONMD
Q4 25
$216.3M
$2.2M
Q3 25
$245.0M
$1.5M
Q2 25
$209.9M
$2.3M
Q1 25
$232.4M
$1.7M
Q4 24
$213.6M
$3.7M
Q3 24
$235.2M
$4.4M
Q2 24
$255.5M
$1.0M
Q1 24
$274.9M
$750.0K
Debt / Equity
ABSI
ABSI
ONMD
ONMD
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.02×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABSI
ABSI
ONMD
ONMD
Operating Cash FlowLast quarter
$-29.2M
$-1.7M
Free Cash FlowOCF − Capex
$-29.3M
$-1.7M
FCF MarginFCF / Revenue
-4505.4%
-193.0%
Capex IntensityCapex / Revenue
15.8%
0.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-94.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABSI
ABSI
ONMD
ONMD
Q4 25
$-29.2M
$-1.7M
Q3 25
$-25.0M
$-1.6M
Q2 25
$-16.9M
$-2.3M
Q1 25
$-21.8M
$-1.9M
Q4 24
$-17.0M
$-2.0M
Q3 24
$-20.7M
$-1.9M
Q2 24
$-16.8M
$-1.5M
Q1 24
$-17.9M
$-1.5M
Free Cash Flow
ABSI
ABSI
ONMD
ONMD
Q4 25
$-29.3M
$-1.7M
Q3 25
$-26.0M
Q2 25
$-17.1M
$-2.3M
Q1 25
$-21.9M
$-2.0M
Q4 24
$-17.0M
$-2.0M
Q3 24
$-20.8M
$-1.9M
Q2 24
$-17.2M
$-1.5M
Q1 24
$-1.6M
FCF Margin
ABSI
ABSI
ONMD
ONMD
Q4 25
-4505.4%
-193.0%
Q3 25
-6876.5%
Q2 25
-2883.0%
-1475.5%
Q1 25
-1854.5%
-1425.5%
Q4 24
-2554.4%
-7811.5%
Q3 24
-1221.6%
-1346.5%
Q2 24
-1352.4%
-663.9%
Q1 24
-626.2%
Capex Intensity
ABSI
ABSI
ONMD
ONMD
Q4 25
15.8%
0.6%
Q3 25
254.5%
0.0%
Q2 25
37.6%
1.9%
Q1 25
2.1%
3.6%
Q4 24
3.5%
134.6%
Q3 24
2.8%
6.3%
Q2 24
26.2%
0.4%
Q1 24
0.0%
2.4%
Cash Conversion
ABSI
ABSI
ONMD
ONMD
Q4 25
Q3 25
Q2 25
-0.77×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons